Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026

Navamedic reported Q2 2026 revenue of NOK 140.3m, up 2.2% YoY, with gross margin improving to 38.4% from 37.3%. The adjusted EBITDA margin surged to 11.3% from 7.4% a year earlier, supported by Prescription Drugs revenues rising to NOK 74.3m from NOK 68.3m and acquisitions contributing NOK 14.5m from the Addiction portfolio acquired in July 2025.

Analysis

The important signal is not the modest revenue step-up, but the step-change in operating leverage: a business that can add a few points of gross margin while keeping opex relatively fixed is likely seeing mix improve toward higher-value prescription products and better procurement discipline. In a small-cap healthcare platform, that usually translates into disproportionate EPS upside over the next 2-4 quarters, even if headline growth stays mid-single-digit.

Second-order, the acquired addiction portfolio is more interesting than the quarterly print itself. If integration is working, Navamedic is likely gaining leverage with wholesalers and pharmacies, which can pressure smaller niche distributors and generic importers that lack a comparable bundled offering. The flip side is that the market may be underestimating working-capital drag, integration spend, and the risk that a portion of the margin expansion is temporary inventory/repricing benefit rather than a durable run-rate.

For the next 1-3 months, the catalyst path is execution commentary: guidance on synergy capture, cross-selling, and whether the higher EBITDA margin is repeatable ex-acquisition. Over 6-18 months, the real question is whether this becomes a platform story with valuation multiple expansion, or just a good quarter with no rerating if the company cannot scale beyond low-teen EBITDA margins. The thesis is falsified if subsequent quarters show flat gross margin, rising receivables/inventory, or no follow-through in contribution from the acquired portfolio.

Contrarian view: the market may be too quick to extrapolate a one-quarter margin improvement into a structural inflection. In this type of business, consensus often misses how much of the earnings quality depends on reimbursement timing, supplier rebates, and deal accounting; if any of those normalize, the margin bridge can unwind quickly. Without a clear valuation anchor or liquid listed peer set, this is more of an alert than a high-conviction trade.

Key Decisions for Investors

• No immediate standalone trade based on this print alone; wait for management guidance on synergy run-rate, working capital, and FY26 margin targets before underwriting a rerating.
• Set a 1-3 month watch item on Nordic small-cap healthcare/distribution peers: if Navamedic confirms durable gross margin >38% and EBITDA margin >11% ex one-offs, the group may support a relative-value long vs lower-quality distributors.
• Use the next quarterly update as the falsification point: if inventory or receivables accelerate faster than revenue, assume the earnings quality is weaker than the headline suggests and fade any post-earnings strength.
• If an accessible peer basket becomes available, consider a pair trade: long higher-quality prescription-distribution platforms, short lower-margin generic importers, but only after confirming the margin improvement is structural rather than acquisition accounting.